Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Discover Agile Therapeutics' patented transdermal drug delivery device, designed to reduce skin irritation and enhance stability for effective seven-day wear.

Global Transdermal Medical Patch Market is valued at approximately USD 7.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2024-2032.

Menopausal hormone therapy reduced the risk for psychosis relapse by 16% in women with schizophrenia or schizoaffective ...

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technologyNutriband ...

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent ...

MedPharm, a global topical and transdermal Contract Development and Manufacturing Organization ("CDMO"), today announced Mr.

2024年欧洲肿瘤内科学会年会（2024 ESMO）将于当地时间2024年9月13日至17日在西班牙巴塞罗那正式召开。一直以来，最新突破性摘要（LBA，Late Breaking Abstracts）都是年会中备受瞩目的焦点。同时，鉴于前列腺癌是我国泌尿男生殖系统最常见的恶性肿瘤，本次ESMO大会公布的前列腺癌重磅进展对于我国前列腺癌诊疗实践具有重要参考价值。

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven ...

Zen Leaf Arcadia, formerly known as Local Joint, relocated from E University Drive to its new home at 2710 E Indian School Road in Phoenix, a ...

Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl ...